Jinhyun Cho

发表

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis

Jinchul Kim, J. Lim, Hyerim Ha, 2022, Journal of Cancer.

Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis

S. Kim, W. Kim, Jinchul Kim, 2021, Hematological oncology.

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical Cancer Research.

Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis

M. Lee, Suk-Jin Choi, Jinchul Kim, 2019, International Journal of Hematology.

J. Ahn, M. Ahn, Keunchil Park, 2020, Oncoimmunology.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma

C. Ki, K. Yoo, S. Kim, 2018, Annals of Hematology.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis

M. Lee, Jinchul Kim, J. Lim, 2018, Scientific Reports.

Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion.

Sung‐A Chang, Eun Kyoung Kim, S. Park, 2020, Journal of the American College of Cardiology.

Life-Threatening Thrombocytopenia Following Intravenous Contrast Media Infusion

Mihwa Park, Jinhyun Cho, Minjeong Kim, 2017, Yonsei medical journal.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.

J. Ahn, M. Ahn, Keunchil Park, 2017 .

Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data

J. Ahn, Yeon-Hee Park, Y. Im, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis

Jinchul Kim, J. Lim, Jinhyun Cho, 2018, Scientific Reports.

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma12

W. Park, K. Jang, Kyung Kim, 2016, Translational oncology.

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Ha Yeon Lee, Sin-Ho Jung, J. Ahn, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults

Junshik Hong, J. H. Lee, K. Yoo, 2020, PloS one.

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma1

C. Park, Jeeyun Lee, H. Lim, 2016, Translational oncology.

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

K. Yoo, K. Jang, S. Choi, 2016, Investigational New Drugs.

HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA

K. Jang, S. Choi, Jinhyun Cho, 2017 .

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea

J. Ahn, Yeon-Hee Park, Y. Im, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis

M. Lee, Jinchul Kim, J. Lim, 2019, Targeted Oncology.

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer

Soon-Sun Hong, K. Jung, Zhenghuan Fang, 2020, Translational oncology.

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

J. Ahn, M. Ahn, Keunchil Park, 2020, Immune network.

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis

M. Lee, Jinchul Kim, J. Lim, 2018, Scientific Reports.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.